SVNS — Solvonis Therapeutics Balance Sheet
0.000.00%
- £17.70m
- £16.06m
- 21
- 11
- 84
- 28
Annual balance sheet for Solvonis Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 0.545 | 1.64 | 0.155 | 0.757 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 0.112 | 0.33 | 0.087 | 0.036 |
| Total Inventory | ||||
| Prepaid Expenses | ||||
| Total Current Assets | 0.657 | 2.16 | 0.314 | 0.815 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | — | 0.701 | 0.039 | 0 |
| Net Intangible Assets | ||||
| Long Term Investments | ||||
| Long Term Notes Receivable | ||||
| Other Long Term Assets | ||||
| Total Assets | 4.33 | 4.94 | 2.43 | 3.2 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 1.91 | 0.367 | 0.386 | 0.119 |
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Liabilities | 1.91 | 0.385 | 0.408 | 0.119 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 2.43 | 4.55 | 2.03 | 3.08 |
| Total Liabilities & Shareholders' Equity | 4.33 | 4.94 | 2.43 | 3.2 |
| Total Common Shares Outstanding |